SEER Inquiry System - Question 20220046 Details

System Guide

Back to Search Results

SEER Inquiry System - Report

Produced: 12/25/2024 3:59 AM

Question 20220046

Export CSV Export PDF Print

Add to Report

Inquiry Details

References:

SEER*Rx

Question:

First Course Treatment/Immunotherapy--Other Therapy: Should IMC-A12 (Cixutumumab) be coded as Immunotherapy/Biological Response Modifier (BRM) treatment? See Discussion.

Discussion:

IMC-A12 (Cixutumumab) is listed as a BRM agent in SEER*Rx, but the Remarks section indicates it should be coded as Other Therapy until there is FDA approval. It is unclear if FDA approval was ever given for this agent. We are mainly seeing it given for prostate primaries.

Answer:

Code Cixutumumab as Other Therapy. Cixutumumab is still in clinical trials and not approved by FDA yet. Though it is classified as an immunotherapy agent, it is not approved.

Cancer Site Category:

N/A

Data Item Category:

First course treatment, Other therapy

Other Category:

N/A

Year:

2022